ORENCIA (ABATACEPT)
ORENCIA (ABATACEPT) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: ORENCIA; Generic name: ABATACEPT; Drug class: Selective T Cell Costimulation Modulator [EPC].
| Brand name | ORENCIA |
|---|---|
| Generic name | ABATACEPT |
| Drug class | Selective T Cell Costimulation Modulator [EPC] |
| Manufacturer | E.R. Squibb & Sons, L.L.C. |
| Used for | 1 INDICATIONS AND USAGE ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 a |
| Dosage | 2 DOSAGE AND ADMINISTRATION Intravenous Use for Adult RA (2.1) and Adult PsA (2.3) • Administer at 0, 2, and 4 weeks, and every 4 weeks thereafter, as a 30-minute infusion Body Weight of Patient Dose Number of Vials Less than 60 kg 500 mg 2 60 to 100 kg 750 mg 3 More than 100 kg 1,000 mg 4 Subcutaneous Use for Adult RA (2.1) • Prior to the first subcutaneous dose, may administer an optional loading dose as a single intravenous infusion as per body weight categories above. • Administer 125 mg by |
| Active ingredient(s) | ABATACEPT |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb |